I avoid Facebook but may consider it for that. But I can generally keep up with this at clinicaltrials.gov and through other sources.
KRAS mutations are extremely common, even dominant, in pancreatic ductal adenocarcinoma (by far the most common kind of pancreatic cancer) so that's driving some of the research in this area. The frequency pattern is pretty similar to what occurs in CRC (G12D, G12V most common followed by other G12 mutations, others much less common).
D/H Dx 10/2019 RC age 61
Clinical T4bN2M1a (common iliac and para-aortic lymph nodes)
MSS KRAS G12D
CRT 11/19-1/20 FOLFOX 3/20-7/20
Pelvic exenteration w/LAR 8/20
ypT4bN0Mx G3 0/14 nodes LVI not seen PNI-
CEA 10/19:20, 1/20-11/20:1.6, 4.3, 3.4, 2.7, 2/21:9.0 3/21:18,40 4/21:28,19, 5/21:13.3,8.6
PET 3/21 recurrence in distal nodes, L5 vertebra, pelvis